Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.

Filed under: Metabolic

Roche’s Ocrevus racks up more positive MS data in relapsing and primary progressive forms

The positive data for Roche’s Ocrevus keep on coming. Friday, the company’s Genentech unit announced that the multiple-sclerosis fighter had significantly cut down disease activity and disability progression in patients with relapsing forms of the disease and those with the harder-to-treat, primary progressive forms.

Filed under: MS

Alzheon says data backs potential of Alzheimer’s candidate

US biotech points to new analysis of phase III results for tramiprosate

Filed under: Alzheimer’s

Novartis heart drug success opens up new care option

A Novartis anti-inflammatory drug cut cardiovascular risk for heart attack survivors in a pivotal trial, potentially changing ideas about treatment.

Filed under: Cardiovascular

Lilly and NRAS launch arthritis awareness film campaign

Pharma firm’s ‘Behind The Smile’ initiative coincides with RA awareness week

Filed under: Arthritis

Pfizer To Lose Exclusivity Of Key Brands

Filed under: Company

Novo gets US backing for Victoza cardiovascular data

US regulatory advisors are backing the claim that Novo Nordisks’ Victoza reduces cardiovascular risk in patients with diabetes.

Filed under: Diabetes, GLP-1

Merck Ventures creates new immuno-oncology company iOnctura

Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT).

Filed under: Cancer, Immunotherapy

Sandoz secures fourth biosimilar approval in Europe with Rixathon

Sandoz, a division of Swiss firm Novartis, has announced that the European Commission has approved its biosimilar Rixathon for the same indications as its reference product rituximab.
These indications include the treatment of blood cancers such as non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia, and immunological disorders including rheumatoid arthritis, granulomatosis with polgyangitis and microscopic polyangitis.
read more

Filed under: Biosimilar

J&J Innovation Reveals New Collaborations in NASH, Diabetes, and Rheumatoid Arthritis

NewsThese new deals will also help advance cutting-edge technologies, including 3-D printing to create customized health solutions.Contributed Author: J&J InnovationTopics: Biotech

Filed under: Company

Parexel, Sanofi explore use of wearables in clinical trial

Six years after Pfizer’s landmark REMOTE trial, Parexel and Sanofi are teaming up in a pilot study to revisit the idea of using wearables in clinical trials.

Filed under: R&D

CVS Point-Of-Sale Rebate Program Adopted By ‘Several’ Payers

Manufacturer rebates can be used to reduce patient cost sharing at point of sale under the PBM’s program.

Filed under: Payer

Sanofi to invest further in biologics

PARIS (Reuters) – Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

Filed under: Company

Canvas Paints A Mixed Picture For J&J’s Invokana

Filed under: Diabetes, SGLT-2

Continuous Manufacturing: Novartis’ experiment in the future of drug production

Continuous manufacturing has long been touted as the future of drug production. Pharmafile approached Novartis for more details about its successes in the area, and the challenges, of developed the new process.
Why did Novartis decide to take the step to experiment in continuous manufacturing processes? 
read more

Filed under: Company

Oral anticoagulants still underutilized in AFib: study

Drugmakers have turned new generation anticoagulants into blockbusters as treatments for strokes and heart attacks, but one area of care where they have made little progress is for treating atrial fibrillation. Cardiology professionals in a new study says that is unfortunate for patients.

Filed under: Cardiovascular

China FDA changes will speed up approval process, says CRO

Proposed changes to drug, medical device and clinical testing regulations provide stimulus for conducting trials in China, says CRO George Clinical.

Filed under: Emerging Markets

AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial

(Reuters) – U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study.

Filed under: Arthritis

Chiesi backs up COPD triple therapy with real world study

Italian firm takes on mighty GSK
The post Chiesi backs up COPD triple therapy with real world study appeared first on Pharmaphorum.

Filed under: COPD

Approval for biomarker-based Keytruda a US FDA first

US FDA has approved a cancer treatment based on a common biomarker, as opposed to the location in the body where the tumour developed.

Filed under: Cancer, Immunotherapy